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  INTRODUCTION 
  Chronic idiopathic constipation (CIC) is a common gastroin-
testinal (GI) condition that aff  ects quality of life and health-care 
expenditures  ( 1 ).  It  has  been  estimated  that  12 – 19 %   ( 2 )  of  the 
general population experiences CIC. Constipation is more oft  en 
reported by females and those over 65 years of age (  2  ). Th  e  symp-
toms of CIC are diverse and include infrequent bowel movements 
(BMs), hard stools, excessive straining, bloating, and abdominal 
discomfort / pain  ( 3 ).  Th   ough a number of over-the-counter and 
prescription medications are available, approximately half of 
patients with CIC are not satisfi  ed with their current treatment 
(  4  ). As such, there remains an unmet need for medical therapies 
and approaches addressing novel physiological mechanisms in 
patients with CIC. 
 Th  e pathophysiology of CIC remains incompletely defi  ned. 
Th   ere is evidence to suggest that modulation of endogenous bile 
acid (BA) homeostasis might off  er a novel therapeutic approach 
to the treatment of CIC. Th   ere are several examples demonstrat-
ing that changes in intracolonic BA concentrations alter bowel 
function: ileal resection results in diarrhea (  5  ), and changes in 
diurnal rates of BA synthesis and colonic BA concentration have 
been identifi  ed in constipated children (  6  ) and in adults with slow 
                                                                         A Randomized Placebo-Controlled Phase IIb Trial 
of A3309, A Bile Acid Transporter Inhibitor, 
for Chronic Idiopathic Constipation       
    William D.             Chey    ,     MD, AGAF, FACG, FACP      1                ,         Michael             Camilleri    ,     MD, AGAF, FACG, FACP      2            ,         Lin             Chang    ,     MD, AGAF      3            ,         Leif             Rikner    ,     MSc      4             
and         Hans             Graffner    ,     MD, PhD      4                           
    OBJECTIVES:       A3309 is a minimally absorbed ileal bile acid (BA) transporter (IBAT) inhibitor. We conducted an 
8-week, multicenter, randomized, double-blind, placebo-controlled, parallel group, phase IIb study, 
which evaluated A3309 in patients with chronic idiopathic constipation (CIC). 
    METHODS:       Patients with CIC (modiﬁ  ed Rome III criteria and       <      3 complete (CSBM) spontaneous bowel move-
ments (SBMs)  /  week during the 2-week baseline) were randomized to 5, 10, or 15    mg A3309 or 
placebo once daily. The primary end point was change in SBM number during week 1 compared with 
baseline. Other bowel and abdominal symptoms were assessed as secondary end points. 
Serum 7  α  C4 and lipids were evaluated as biomarkers of BA synthesis  /  loss. 
    RESULTS:       In all, 190 patients (mean 48 years, 90  %   female) were randomized. Mean increase (95  %   conﬁ  dence 
interval) in SBM for week 1 were 1.7 (0.7  –  2.8) for placebo vs. 2.5 (1.5  –  3.5), 4.0 (2.9  –  5.0), and 
5.4 (4.4  –  6.4) for 5    mg, 10    mg (  P        <      0.002), and 15    mg (  P        <      0.001) A3309, respectively. Increased 
stool frequency was maintained over 8 weeks. Time to ﬁ  rst SBM and CSBM were signiﬁ  cantly 
reduced in the 10- and 15-mg A3309 groups compared with placebo. Straining and bloating 
decreased with A3309 compared with placebo (  P        <      0.05). Increased 7  α  C4 and reduced low-density 
lipoprotein cholesterol with A3309 suggested increased BA synthesis and BA loss. The most 
common adverse events (AEs) were abdominal pain and diarrhea, which occurred most commonly 
in the 15-mg A3309 group. No drug-related serious AEs were observed. 
    CONCLUSIONS:       A3309 increased stool frequency and improved constipation-related symptoms in CIC; effects were 
maintained over 8 weeks of treatment.     
    SUPPLEMENTARY MATERIAL   is linked to the online version of the paper at   http://www.nature.com/ajg     
   Am J Gastroenterol   2011;  106:1803–1812;   doi: 10.1038/ajg.2011.162;  published  online  24  May  2011         
            1      Department of Medicine, University of Michigan Health System  ,   Ann Arbor  ,   Michigan  ,   USA      ;                 2      Mayo Clinic  ,   Rochester  ,   Minnesota  ,   USA      ;                 3      David Geffen School 
of Medicine at UCLA  ,   Los Angeles  ,   California  ,   USA      ;                 4      Albireo  ,   Goteborg  ,   Sweden      .                Correspondence:           William D. Chey, MD, AGAF, FACG, FACP  ,     Department of 
Medicine, University of Michigan Health System  , 3912 Taubman Center, SPC 5362,   Ann Arbor  ,   Michigan     48109-5362  ,   USA  . E-mail:   wchey@med.umich.edu     
  Received 27 January 2011; accepted 12 April 2011 The American Journal of GASTROENTEROLOGY  VOLUME 106 | OCTOBER 2011   www.amjgastro.com
1804
 
F
U
N
C
T
I
O
N
A
L
 
G
I
 
D
I
S
O
R
D
E
R
S
 
  Chey   et al.   
transit constipation and constipation-predominant irritable bowel 
syndrome (IBS-C) (  7,8  ). Conversely, decreasing free BA concen-
trations in the colon through the use of the BA sequestrant choles-
tyramine induces constipation (  5  ), and another BA sequestrant, 
colesevelam, retards accelerated colonic transit in patients with 
IBS-D (  9  ). 
  Inhibitors of the ileal BA transporter (IBAT; syn ASBT  — 
apical sodium-dependent BA transporter) reduce the active ileal 
reabsorption of BA, resulting in an increased concentration of 
BA entering the colon, thereby stimulating colonic motility and 
secretion (  10  ). BAs induce propulsive contractions in the human 
colon (  11  ), secretion through activation of adenylate cyclase (  12  ), 
increased mucosal permeability (  13  ), and inhibition of apical Cl      −       /
 OH     −        exchange (  14  ). Th  ese  eff  ects on colonic motility and secre-
tion may off  er clinical benefi  ts in patients with CIC. A3309 is a 
selective inhibitor of the IBAT, which has been shown to reduce 
meat-induced constipation in the dog (  15  ). In humans, A3309 
accelerated colonic transit in a multiple ascending dose, phase Ib 
study in patients with CIC (  16  ). 
 Th   e current phase IIb study in patients with CIC was performed 
to assess the short-term effi   cacy and safety of orally administered 
A3309 at 5, 10, and 15      mg doses, compared with placebo, once 
daily for 8 weeks.     
  METHODS   
  Study design: randomization and protocol 
  A randomized, double-blind, placebo-controlled study was con-
ducted at 45 sites across the United States between November 
2009 (fi  rst signed informed consent) and August 2010 (last patient 
visit). Th   e study was conducted in accordance with the Declaration 
of Helsinki and with Good Clinical Practice guidelines. Written 
informed consent was obtained from all patients before participa-
tion. Central or local Ethical Review Boards approved the study 
protocol and the informed consent form. Th   e study was registered 
on ClinicalTrial.Gov [NCT01007123]. Treatment allocation and 
concealment were conducted by a computerized random-number 
generator and numbered containers with active and placebo 
capsules of identical appearance. Th   e randomization list was cen-
trally held by an independent Contract Research Organization, 
all randomized patients and study center and contract research 
organization personnel were blinded to study treatment alloca-
tion until data were locked and analyzed. 
 Aft  er informed consent was obtained, patients entered an initial 
screening period of up to 28 days during which routine blood tests, 
urinalysis, and pregnancy testing were obtained. Where appropri-
ate, patients were taken off   of laxatives and other prohibited medi-
cations. Specifi  c washout periods (3- or 10-day periods based on 
duration of action) were used for prohibited medications. Bulking 
agents and stool soft  eners were allowed if the patient was taking 
a stable dose for at least 30 days before the start of the screen-
ing period. Th   e use of rescue medication (bisacodyl suppository) 
was permitted following consultation with the investigator if the 
patient  had      >    72   h  without  a  BM.  Patients  meeting  the  inclusion 
and exclusion criteria entered a 14-day pretreatment baseline 
period. Patients eligible to continue were randomized to receive a 
5-, 10-, or 15-mg tablet of A3309 or placebo orally once daily before 
breakfast for 8 weeks. During the 14 days before randomization 
and during the treatment period, patients reported daily bowel and 
abdominal symptoms using an Interactive Voice Response System. 
Study visits occurred during the screening period, at randomiza-
tion (day 0), during treatment (day 28), at end of treatment (day 
56), and 14 days post-treatment (day 70).     
  Study medication 
  Pharmacokinetic studies show that orally administered A3309 
leads to minimal systemic exposure and that systemically avail-
able  drug  is  highly  protein  bound  (    >    99 % )  ( 15 ).   
  Study participants 
  Eligible patients were men or non-pregnant women, 20  –  80 years 
of age, who met modifi  ed Rome III criteria for functional consti-
pation  ( 17 ),  with  a  diagnosis  of      >    3  months  and  with  symptom 
onset at least 6 months before diagnosis. Study participants were 
required to have a baseline BM frequency of        <       3 complete spon-
taneous BMs (CSBMs) per week. In addition,   ≥  2 of the following 
characteristics that are included in the Rome III criteria for func-
tional constipation were required during the 14 days before ran-
domization: (1) straining during   ≥ 25 %   of  BMs,  (2)  sensation  of 
incomplete evacuation in   ≥  25  %   of BMs, (3) lumpy or hard stools 
in   ≥ 25 %   of  BMs,  or  (4)  sensation  of  blockage / anorectal  obstruc-
tion in   ≥  25  %   of BMs. Eligible patients had a body mass index 
of      >    18.0  and      <    35   kg / m 2  . Patients were excluded if they had been 
previously diagnosed with constipation-predominant IBS, had 
abdominal pain as a predominant symptom, or had drug-induced 
constipation. Also, patients were excluded if they reported the 
need for manual maneuvers (digital insertion into the rectum, 
perianal pressure, or vaginal splinting) or frequent use of enemas 
to evacuate stool. Other exclusion criteria included known rectal 
prolapse, dyssynergic defecation (per patient history and clinical 
examination), previous intestinal resection, neurological cause of 
constipation, and use of drugs with known eff  ects on GI motility 
or stool consistency. Patients reporting loose or liquid stool con-
sistency by a Bristol Stool Form Scale score of 6 or 7 (unless within 
24     h of having taken a laxative) at least once during the screening 
period were excluded (  18  ). Patients with persistent constipation 
symptoms despite a stable dosage of bulking agents for        >       4 weeks 
were eligible. 
  All study participants were required to meet the colorectal can-
cer screening requirements of the American Gastroenterological 
Association Guidelines (  19  ). Women of child-bearing age were 
required to have a negative serum pregnancy test; those who were 
sexually active were required to use an accepted form of birth con-
trol during their participation in the study.     
  Outcome measures and assessments 
 Th   e primary end point of the study was the change from baseline 
in frequency of weekly spontaneous bowel movements (SBMs) 
at week 1. Secondary effi   cacy end points included weekly assess-
ment of SBMs and CSBMs, daily assessments of other bowel-© 2011 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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  The ASBT  /  IBAT Inhibitor A3309 in Constipation 
related complaints (i.e., stool consistency and straining), and 
abdominal symptoms (i.e., pain, discomfort, and bloating). Th  e 
time to onset of clinical effi   cacy was evaluated by   “  time to fi  rst 
SBM  ”   and   “  percentage of patients having an SBM within 24     h of 
fi  rst administration of study drug.  ”   Similar assessments for CSBM 
were also performed. In addition, we chose to look at the stool 
frequency responder end point included in a recent US Food and 
Drug Administration guidance document (  20  );   “  CSBM stool fre-
quency  responder ”   was  defi  ned as a patient who had an increase 
of   ≥  1 CSBM per week over baseline for at least 4 of the 8 weeks of 
the treatment period.     
  Daily symptom assessments 
  Assessments were recorded by phone using Interactive Voice 
Response System. Each day, patients recorded the time study 
medication was taken and the number and time of each BM. Th  e 
characteristics of each BM were assessed using the 7-point Bristol 
Stool Form Scale ( 18 ). Th   e severity of straining was graded using a 
5-point ordinal scale (1    =    not at all, 2    =    a little bit, 3    =    more straining 
than  not,  4    =    a  great  deal,  and  5    =    an  extreme  amount).  SBM  was 
defi  ned as a BM in which no laxative, enema, or suppository was 
used in the preceding 24     h, and a CSBM was defi  ned as an SBM, 
which was associated with a feeling of complete bowel emptying. 
Each day, patients also recorded the severity of bloating, pain, and 
discomfort  using  5-point  scales  (1    =    none,  2    =    mild,  3    =    moderate, 
4    =    severe,  and  5    =    very  severe)  and  any  use  of  rescue  medication.   
  Surrogate markers of hepatic synthesis and GI loss of BAs 
 Mechanistic  eff  ects of A3309 on hepatic BA synthesis rates were 
evaluated using plasma C4 (7  α -hydroxy-4-cholesten-3-one)  ( 21 ) 
and on plasma lipids (total cholesterol, low-density lipoprotein 
(LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, 
and triglycerides) using a high-performance liquid chromatogra-
phy  method.   
  Safety assessment 
 Th  e    intensity   of adverse events (AEs) was reported by patients as 
mild, moderate, or severe. Separate from AE intensity, patients 
were defi  ned as suff  ering from a serious AE (SAE) if the AE 
resulted in death, was deemed life threatening, led to long-term 
disability, or required or prolonged hospitalization for treatment. 
Th   e site investigator assessed all patient-reported AEs and deter-
mined their relationship to study treatment. Safety evaluations 
included physical examinations, electrocardiogram, vital signs 
measurements, and standard laboratory tests (clinical chemistry, 
hematology, fat-soluble vitamins [A, D, E], and coagulation).     
  Statistical methods and data analysis 
 Patients were randomized in a 1:1:1:1 ratio to the treatment groups. 
Th   e sample size for this study was selected to provide 80  %   power 
to detect a diff  erence of 2.5 SBMs per week between an active 
treatment group and the placebo group using a two-sided   t -test 
at     α       =    0.05  signifi  cance without adjustment for multiplicity. Th  is 
calculation was based on the assumption that treatment groups 
have unequal variances (estimated active s.d.       =       4.7, estimated pla-
cebo  s.d.    =    2.6).  Th  irty-eight patients per treatment group were 
required to achieve the desired power under the stated assump-
tions. To allow for a withdrawal rate of 15  %  , 45 patients per group 
(180 patients total) were required. 
  All changes from baseline end points were analyzed with a 
one-way analysis of covariance, with a fi  xed eff  ect for treatment 
group and the baseline value of SBMs used as a covariate. Within 
the analysis of covariance, each dose of A3309 was compared with 
placebo in a pairwise manner. Th   e time to the fi  rst SBM and the 
fi  rst CSBM were analyzed using a one-way analysis of variance, 
with a fi  xed eff  ect for treatment group. Th   e binary response end 
point   “  CSBM stool frequency responder  ”   was analyzed with Fish-
er  ’  s exact test comparing each A3309 dose with placebo. 
  An observed-cases approach to missing data was applied (i.e., 
a patient  ’  s missing values were not imputed or carried forward). 
All   P   values are based on two-sided tests and given that this was a 
phase IIb dose-range fi  nding study, the reported   P   values were not 
adjusted for multiple comparisons. Patients discontinuing treat-
ment were defi  ned as treatment failures for the responder analyses. 
 Effi   cacy analyses are reported for the ITT (intent to treat) popu-
lation defi  ned as all randomized patients who received at least one 
dose of study medication and had any post-baseline patient diary 
data (BM or GI symptoms) collected (  n     =    190). 
  Evaluations of serum C4 and lipids, which refl  ect pharmaco-
dynamic eff  ects of A3309, were performed on the completer per 
protocol population ( n     =    121) defi  ned as all ITT patients who com-
pleted the study and were at least 80  %   compliant with study medi-
cation and patient reports during the treatment period. 
  Safety results are reported for the safety population (  n     =    189) 
defi  ned as all randomized patients who received at least one dose 
of study treatment and for whom follow-up safety data are avail-
able. Assessments of safety were performed evaluating number  /
  proportions of patients experiencing SAEs  /  AEs and with an 
analysis of any changes from baseline in laboratory safety tests, 
electrocardiogram, and vital signs.       
  RESULTS   
  Patient ﬂ  ow and follow-up 
  Of 448 CIC patients screened, 190 were randomized and 161 
completed the study (  Figure 1  ). At baseline, the demographic 
parameters were similar between the treatment groups (  Table 1 ). 
Patients had a mean age of 48.1 years (range 20  –  79), and were 
predominantly female (90  %  ) and white (78  %  ). Th   e mean number 
of SBMs and CSBMs per week at screening was 2.82 and 0.40, 
respectively. Full baseline characteristics of our study population 
can be found in   Supplementary Appendix Table 1   online.   
  Bowel function 
   Stool frequency      .     At week 1 of the double-blind treatment phase 
(primary effi   cacy end point), patients treated with 10 or 15     mg of 
A3309 reported a signifi  cantly (  P     <    0.002  and   P     <    0.001,  respec-
tively) greater change from baseline in the number of SBMs com-
pared with placebo;   Figure 2   shows a clear dose  –  response with 
mean (95  %   confi  dence interval) increases of 2.5 (1.5  –  3.5, NS), The American Journal of GASTROENTEROLOGY  VOLUME 106 | OCTOBER 2011   www.amjgastro.com
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4.0 (2.9  –  5.0,   P     <    0.002),  and  5.4  (4.4 – 6.4;   P     <    0.001)  SBMs  for  the 
A3309 dose levels of 5, 10, and 15     mg, compared with an increase 
of 1.7 (0.7  –  2.8) SBMs for placebo. Th  e  benefi  cial eff  ect of A3309 
on weekly SBM ( Figure 3a ) and CSBM ( Figure 3b ) frequency was 
maintained over placebo for the 8-week treatment period. 
 A3309 at doses of 10 and 15   mg signifi  cantly reduced the time to 
fi  rst SBM relative to placebo ( P     =    0.033 and 0.039, respectively); an 
SBM occurred (mean) 12 and 7     h aft  er fi  rst dose of A3309 10 and 
15   mg, respectively, compared with (mean) 27   h for placebo. A sig-
nifi  cantly higher proportion of patients reported an SBM within 
24     h of taking their fi  rst dose of A3309 at a dose of 10 (74  %  ) or 
15   mg  (75 % )  compared  with  placebo  (45 % )  ( P     =    0.012  for  both). 
When considering time to fi  rst CSBM or the proportion who re-
ported a CSBM within 24     h of dosing, signifi  cant diff  erences were 
again observed with the two higher doses of A3309 compared 
with placebo (  P  ≤  0.02 for all comparisons). 
  CSBM stool frequency responder rates were also signifi  cantly 
improved with all three A3309 dose levels compared with pla-
cebo;  58 %   (25 / 43),  64 %   (27 / 42),  75 %   (30 / 40)  for  the  5,  10,  and 
15      mg groups compared with placebo (33  %  , 14  /  42) (  P     =    0.030, 
0.008,      <    0.001,  respectively).   
  Stool consistency and straining   .    Patients  treated  with  10  and 
15     mg doses of A3309 reported signifi  cant improvements in stool 
consistency and signifi  cant decreases in straining at all treatment 
weeks (  P     <    0.001  for  all  comparisons)  ( Figure 4a and b ).    
  Abdominal symptoms 
   Bloating, pain, and discomfort   .     Th   e mean change from baseline 
in overall bloating across the 8-week treatment period improved 
in patients receiving the 15-mg dose of A3309 (  P     =    0.048)  ( Figure 
4c ). Th   ere were no diff  erences in eff  ects on abdominal pain or dis-
comfort between the A3309 groups and placebo.       
  Rescue medication use 
 Th   ere were no signifi  cant diff  erences in the use of rescue medica-
tion between active treatment groups and placebo at any of the 
study  intervals.   
  Surrogate markers of hepatic BA synthesis and GI loss 
  Plasma C4 increased in all of the active A3309 dose levels with 
mean ( ± s.e.m.) changes from baseline being 1.2 ( ± 4.2) for placebo, 
14.9 (  ±  4.0) for the 5-mg group, 21.1 (  ±  4.4) for the 10-mg group, 
Patients screened, n=448
Excluded (n=258)
￿ Not meeting inclusion criteria (n=244)
￿ Declined to participate (n=11)
￿ Other reasons (n=3)
Enrollment
Placebo n=47
Placebo n=47
Discontinuation (n=6)
due to
AE n=1
Lack of efficacy n=4
Protocol violation n=1
Patient withdrawal n=0
Lost to follow-up n=0
Discontinuation (n=6)
due to
AE n=3
Lack of efficacy n=1
Protocol violation n=1
Patient withdrawal n=1
Lost to follow-up n=0
Discontinuation (n=6)
due to
AE n=4
Lack of efficacy n=0
Protocol violation n=1
Patient withdrawal n=0
Lost to follow-up n=1
Discontinuation (n=11)
due to
AE n=7
Lack of efficacy n=1
Protocol violation n=2
Patient withdrawal n=1
Lost to follow-up n=0
Placebo n=47 Placebo n=47 Placebo n=47
A3309 5 mg n=48 A3309 10 mg n=47 A3309 15 mg n=48
Patients randomized n=190
Allocation
Follow-up
Analysis
Safety population n=47
ITT population n=47
Completer population
n=33
Safety population n=48
ITT population n=48
Completer population
n=37
Safety population n=46
ITT population n=47
Completer population
n=29
Safety population n=48
ITT population n=48
Completer population
n=22
    Figure 1  .                 Patient ﬂ  ow diagram. Completer PP (per protocol) population      =      all intention to treat (ITT) patients who completed the study and were at least 80  %   
compliant with study medication and patient reports during the treatment period. AE, adverse event.   © 2011 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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placebo caused signifi  cant changes in plasma HDL cholesterol or 
triglycerides.   
  Safety assessment 
  AEs were reported in 102 of the 189 patients (54  %  ); 14 patients (7  %  ) 
had events of   severe intensity.   Th   e main diff  erence between the groups 
was that fi   ve patients in the 15-mg A3309 group had abdominal 
cramping / pain and / or diarrhea of severe intensity. Treatment-emergent 
SEs occurred in 44, 46, 62, and 65  %   in the placebo, 5, 10, 15     mg A3309 
groups, respectively. Th   e most common AEs were of GI origin including 
abdominal pain (0, 10, 11, and 27 % ) and diarrhea (2, 8, 6, and 13 % ). 
  In total, 29 patients (15  %  ) discontinued study medication (pla-
cebo: 12.8  %  , 5     mg A3309: 12.5  %  , 10     mg A3309: 12.8  %  , and 15     mg 
A3309: 22.9  %  ).   Table 3   outlines the treatment-emergent AEs and 
discontinuations during the study. Th  e rate of AEs and discon-
tinuations was greater in the 15-mg A3309 group compared with 
the 5- or 10-mg A3309 or placebo groups. Discontinuations due 
to GI AEs are outlined in   Table 3 . 
 Th   ree SAEs were reported, one in the placebo group (shoulder 
pain), one in the 5-mg A3309 group (colonoscopy verifi  ed bleed-
ing colonic diverticulum 2 weeks aft  er the end of treatment), and 
one in the 10-mg A3309 group (breast carcinoma diagnosed on 
day 5 of treatment). None of the SAEs were considered related to 
the study drug. No deaths occurred during the study. 
 Th   ere were no diff  erences in the incidence of clinically signifi  -
cant changes in laboratory parameters, vital signs, or other safety 
parameters.    
and 12.9 (  ±  5.1) for the 15-mg group (  P     =    0.020,  0.002,  and  0.082, 
respectively).  Baseline  total  cholesterol  levels  were      >    200   mg / dl  in 
43  %   of the patients; the mean (  ±  s.e.m.) baseline total plasma cho-
lesterol level was 195 (  ±  5.2) mg  /  dl (ITT population). Signifi  cant 
decreases in total cholesterol were observed for the 10- and 15-mg 
dose levels (  P     =    0.014  and   P     =    0.027,  respectively).  Compared  with 
baseline, LDL cholesterol and the LDL  /  HDL ratio each decreased 
while on treatment with A3309 (  Table 2  ). Neither A3309 nor 
    Table 1  .       Patient demographics  —  ITT population     
           Placebo       A3309       Overall   
              5    mg       10    mg       15    mg      
         N     47   48   47   48   190 
        Age, years   
           Mean   49.9   48.0   48.4   46.2   48.1 
           Min  –  max   21  –  72   20  –  79   22  –  66   20  –  72   20  –  79 
        Age group   
                 <      60 years    33 (70.2)    40 (83.3)    39 (83.0)    40 (83.3)    152 (80.0) 
             ≥  60 years    14 (29.8)    8 (16.7)    8 (17.0)    8 (16.7)    38 (20.0) 
        Gender   
           Male   8 (17.0)    5 (10.4)    2 (4.3)    5 (10.4)    20 (10.5) 
           Female   39 (83.0)    43 (89.6)    45 (95.7)    43 (89.6)    170 (89.5) 
        Race,   n   (%)   
           White   35 (74.5)    41 (85.4)    36 (76.6)    36 (75.0)    148 (77.9) 
           Black/African American    12 (25.5)    7 (14.6)    10 (21.3)    12 (25.0)    41 (21.6) 
        BMI, kg/m      2    
           Mean   26.87   26.09   27.09   27.71   26.94 
           s.d.   4.330   4.327   3.728   3.841   4.076 
          BMI, body mass index; ITT, intention to treat; min  –  max, minimum and maximum age.     
          Numbers in parentheses are percentages.     
7
6
5
4
3
2
1
0
Placebo 5 mg 10 mg 15 mg
5 mg vs. placebo P=0.236
10 mg vs. placebo P<0.002
15 mg vs. placebo P<0.001
**
***
Change in # of SBMs
Least squares mean (95% confidence interval) – ITT population
    Figure 2  .                 Change from baseline in weekly spontaneous bowel movement 
(SBM) frequency for treatment week 1. ITT, intention to treat.   The American Journal of GASTROENTEROLOGY  VOLUME 106 | OCTOBER 2011   www.amjgastro.com
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9 6
# of CSBMs/week
5
4
3
2
1
0
BL 1 2 3 4 5 6
ITT population
7 8 weeks
8
7
6
5
4
3
2
1
0
B L 12345678 w e e k s
ITT population
# of SBMs/week
Placebo 5 mg 10 mg 15 mg
***
*
***
*
*
Placebo 5 mg 10 mg 15 mg
      Figure 3  .                 Effect of A3309 and placebo on weekly stool frequency. Mean weekly SBM (  a  ) and CSBM (  b  ) frequency. Signiﬁ  cance values shown are for the 
overall change from baseline between A3309 and placebo.   *    *    *    P        <      0.001,   *    P        <      0.05. CSBM, complete spontaneous bowel movement; ITT, intention to treat; 
SBM, spontaneous bowel movement.   
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      Figure 4  .                 Effect of A3309 and placebo on weekly stool consistency, straining, and bloating. Changes in stool consistency (  a  ), straining (  b  ), and bloating (  c  ) over 
the treatment period. Signiﬁ  cance values shown are for the overall change from baseline between A3309 and placebo.   *    *    *    P        <      0.001,   *    P        <      0.05. BSFS, Bristol 
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ments in other constipation-associated symptoms (stool con-
sistency, straining, and bloating). Th  ere was also benefi  t for the 
rigorous CSBM stool frequency responder defi  nition (an increase 
of   ≥  1 CSBM per week over baseline for at least 4 of the 8 weeks 
of the treatment period), with all doses of A3309 compared with 
placebo. Th  e  eff  ects of A3309 on the frequency and consistency 
of BMs occurred within the fi  rst week of drug administration 
and were maintained over the full 8 weeks of treatment. Roughly 
three quarters of the patients in the 10- and 15-mg A3309 groups 
reported passing an SBM within 24      h of initial drug dosing. 
Importantly, there was no diminution of the clinical benefi  ts of 
A3309 over time, suggesting that there was no development of 
tolerance. 
  It has long been known that BAs are physiological promoters 
of colonic secretion and motility (  10  ). Reduced synthesis and  /  or 
colonic concentrations of specifi  c BAs have been associated with 
the  development  of  constipation  ( 6 – 8 ).  Th   erefore, recent work has 
investigated the potential role of raising colonic BA concentration 
(by direct supplementation or through prevention of ileal reab-
sorption) as a novel target for new drug development in patients 
with CIC (  8,16  ). BAs are mainly absorbed in the ileum by a spe-
cifi  c BA transporter or IBAT. Th   e IBAT is an integral brush bor-
der membrane glycoprotein that co-transports sodium and BAs. 
Available evidence suggests that the IBAT is a major regulator of 
the BA pool in animals and humans. BA reabsorption from the 
intestine is very effi   cient; 95  %   of the secreted BAs are reabsorbed 
and delivered back to the liver completing the process of enterohe-
patic circulation (  22  ). 
  IBAT inhibitors prevent the reabsorption of BAs from the ileum 
and consequently, their return to the liver. Th   e liver compensates 
  DISCUSSION 
 Th   is randomized, placebo-controlled trial evaluated the effi   cacy 
and safety of three doses of the novel IBAT inhibitor, A3309 in 
patients with CIC. Compared with placebo, A3309 signifi  cantly 
increased SBMs during week 1 (the primary end point) and each 
subsequent week of the 8-week treatment period. A3309 also sig-
nifi  cantly increased weekly CSBMs, an end point that includes the 
patient  ’  s qualitative assessment of completeness of a bowel move-
ment and arguably provides an even more rigorous assessment 
of stool frequency than SBM. A3309 led to signifi  cant improve-
    Table 2  .       Mean change from baseline for plasma LDL and 
LDL/HDL ratio     
           Placebo       A3309   
              5    mg       10    mg       15    mg   
         N     32   37   29   22 
        LDL   
           Mean change    2.6         −      2.4         −      15.6***         −      11.1** 
           s.d.   17.30   15.61   18.23   22.90 
        LDL/HDL   
           Mean change          −      0.024         −      0.111         −      0.287**         −      0.221* 
           s.d.   0.333   0.405   0.318   0.393 
          HDL, high-density lipoprotein; ITT, intention to treat; LDL, low-density lipoprotein.     
          Completer PP (per protocol) population (all ITT patients who completed the 
study and were at least 80% compliant with study medication and patient 
reports during the treatment period).     
          ***  P        <      0.001, **  P  =0.01,*  P        <      0.05.     
      Table 3  .       Discontinuations and related treatment-emergent gastrointestinal adverse events (TEAEs)     
           Placebo (  N   = 46)      A3309 5    mg (  N   = 48)      A3309 10    mg (  N   = 47)      A3309 15    mg (  N   = 48)  
      Any TEAE,   n   (%)    20 (44)    22 (46)    29 (62)    31 (65) 
      Treatment discontinuations    6 (12.8)    6 (12.5)    6 (12.8)    11 (22.9) 
        Gastrointestinal disorders   
           Total   5 (10.9)    12 (25.0)    11 (23.4)    19 (39.6) 
           Mild   2 (4.3)    6 (12.5)    5 (10.6)    6 (12.5) 
           Moderate   2 (4.3)    5 (10.4)    4 (8.5)    8 (16.7) 
           Severe   1 (2.2)    1 (2.1)    2 (4.3)    5 (10.4) 
           Abdominal pain    0   5 (10.4)    5 (10.6)    a       13 (27.1)    a        a        a        a         
           Diarrhea   1 (2.2)    4 (8.3)    3 (6.4)    a         6 (12.5)    a        a        a        a            
           Abdominal distension    1 (2.2)    4 (8.3)    2 (4.3)    a       3 (6.3)    a        a     
           Flatulence   3 (6.5)    4 (8.3)    3 (6.4)    a       2 (4.2) 
           Nausea   2 (4.3)    2 (4.2)    2 (4.3)    3 (6.3) 
           Defaecation urgency    0   0   0   2 (4.2) 
           Abdominal pain upper    1 (2.2)    1 (2.1)    0   1 (2.1) 
      a        Drug withdrawn.     
          Numbers in parentheses are percentages.     The American Journal of GASTROENTEROLOGY  VOLUME 106 | OCTOBER 2011   www.amjgastro.com
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for the decrease in BAs by upregulating cholesterol 7  α -hydroxy-
lase, the rate-limiting enzyme for BA synthesis. Th  is results in 
increased levels of 7  α  -hydroxy-4-cholesten-3-one (C4), an inter-
mediate in BA synthesis. In addition, lower hepatic cholesterol 
levels and increased number of LDL receptors in the liver occur 
leading to reduced plasma LDL cholesterol (  23,24  ). Th  ese con-
cepts were confi  rmed in our study where A3309 but not placebo 
resulted in increased C4 values and decreased plasma total and 
LDL cholesterol levels, consistent with increased BA synthesis due 
to inhibition of IBAT. A3309  ’  s cholesterol-lowering eff  ect may be 
an incremental attribute of this treatment that may prove useful in 
patients with CIC. 
 Th  e improvements to constipation symptoms observed with 
A3309 are likely the consequence of increased delivery of BAs to 
the colon leading to increased fl  uid secretion and motility and 
resultant acceleration of transit. Th  is suggestion is supported by 
a recent single center, randomized, double-blind dose escalation 
study in 30 patients with CIC, which found that A3309 signifi  -
cantly accelerated colon transit measured by radio-opaque mark-
ers and increased stool frequency compared with placebo (  16  ). 
  Contrary to the clear benefi  t of A3309 for constipation-asso-
ciated symptoms, there was no statistically signifi  cant diff  erence 
in abdominal pain or discomfort ratings between the A3309 and 
placebo groups. Th   e interpretation of these fi  ndings may be con-
founded by low baseline scores for abdominal pain and discomfort 
(fl  oor eff  ect) likely resulting from the exclusion of patients with a 
prior history of IBS or abdominal pain or discomfort as a predomi-
nant complaint. Further evaluation of A3309 in patients with IBS-
C should be considered to more defi  nitively evaluate the impact of 
this drug on abdominal pain and abdominal discomfort. 
  A3309 was generally well tolerated and no SAEs related to the 
study drug were reported. Th   ere was a dose-related trend in the 
number of AEs and in the percentage of patients discontinu-
ing treatment. Because A3309 has a very low systemic exposure 
(resulting in estimated plasma concentrations in the picomolar 
range), it is reasonable to speculate that AEs, which were largely GI 
in origin, were the consequence of the increased concentration of 
colonic BAs (  11,25  ). 
  Based upon data from this phase IIb dose-range study, it appears 
that the 10-mg dose of A3309 provided the best balance of effi   cacy 
and safety in patients with CIC. Patients on the 15-mg dose level 
had more AEs of abdominal pain and diarrhea. It is conceivable that 
this may refl  ect a direct eff  ect of the higher dose of A3309 on motil-
ity, rather than a secondary eff  ect on transit arising from increased 
colonic secretion. Concentrations of     >    5   m M  of BAs infused directly 
into the human rectum and sigmoid stimulate colonic phasic con-
tractions (  11  ); in addition, Bampton   et al.   ( 26 )  observed  HAPCs  in 
the colon with administration of 1     m  M   chenodexoycholate into the 
rectum of healthy volunteers. Such concentrations of 1  –  5     m  M   BAs 
are seldom achieved in the absence of ileal resection (  27  ). 
  Despite the chronic nature of CIC, many patients use medical 
therapy intermittently; the speed of onset of A3309 is also poten-
tially benefi  cial as it signifi  cantly shortened the time to fi  rst SBM 
and CSBM. Treatment with A3309 may therefore be suited for indi-
vidualized treatment, either on a fi  xed schedule or   “  on demand.  ”   
Further studies specifi  cally designed to address these potential 
uses for A3309 in CIC patients are eagerly awaited. 
  Forty-three percent of CIC patients enrolled in this study had 
baseline total plasma cholesterol values above the desirable cut-
off   level of 200     mg  /  dl. A3309 treatment induced a decrease in LDL 
cholesterol and in the important predictor of cardiovascular dis-
ease — the  LDL / HDL  ratio — (14 %   decreases  in  the  10-mg  dose 
group for both variables). Th  e  benefi  cial eff  ects on lipid profi  le are 
a unique feature of A3309 among current medications and those 
in the pipeline for treatment of CIC. Th   is improvement in serum 
lipids might provide incremental benefi  ts to a subset of patients 
with CIC. 
  When considering our results, several additional issues merit 
discussion. As is common in drug trials of this size, a large number 
of investigative sites were included and patient-reported outcomes 
were captured using an Interactive Voice Response System or with 
electronic handheld devices. Studies that rely upon electronic data 
capture might bias the randomized population toward a younger, 
more affl   uent demographic. What eff  ect, if any, this could have on 
our results is unknown. Patients with CIC entered into this study 
were required to be passing fewer than 3 CSBMs per week. Th  is 
may limit the generalizability of our data to the entire population 
of CIC patients. Acknowledging this point, the decision for this 
entry requirement was largely predicated upon current regulatory 
recommendations, which support stool frequency as the primary 
outcome for trials evaluating therapies for CIC. Further, though 
weekly CSBM rate was used to determine study eligibility, weekly 
SBM rate aft  er the fi  rst week of therapy served as the primary out-
come measure. Th   is primary outcome was chosen aft  er consulta-
tion with the US Food and Drug Administration. In addition to 
meeting the primary outcome, the two higher doses of A3309 pro-
vided robust and signifi  cant benefi  ts to the rate of weekly SBMs 
and CSBMs for the entire 8-week treatment period. One further 
point, which merits consideration, is that our study population 
likely included a subset of patients with dyssynergic defecation. 
Th   e study protocol called for the exclusion of patients with a his-
tory of dyssynergic defecation or in whom the history and physical 
examination was felt to indicate the presence of this type of consti-
pation. We acknowledge that this is an imperfect way of identify-
ing patients with dyssynergic defecation and that the inclusion of 
such patients could have aff  ected the study results. However, we 
would point out that nearly all other recently performed trials eval-
uating novel drug therapies for chronic constipation have handled 
the issue of dyssynergic defecation in a similar manner (  28,29  ). In 
addition, randomization would be expected to level the eff  ect of the 
inclusion of such patients on results yielded by the study groups. 
We would also argue that the practice used in this protocol closely 
mimics clinical practice where diagnostic testing for dyssynergic 
defecation is typically reserved for patients who have failed multi-
ple laxative therapies as recommended by the American Gastroen-
terological Association (  30  ) and the Rome Foundation (  31  ). 
  In conclusion, the results of this placebo-controlled, dose-range, 
phase IIb study in CIC patients demonstrated that the IBAT inhibi-
tor A3309 signifi  cantly improved BM frequency, stool consistency, 
and constipation symptoms. Th   e 10-mg dose of A3309 provided © 2011 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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the best balance of effi   cacy and safety. Further large clinical trials 
evaluating the effi   cacy of A3309 in patients with CIC and IBS-C 
are warranted.        
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 Study  Highlights 
    WHAT IS CURRENT KNOWLEDGE   
   3  Alterations in bile acid metabolism and decreased colonic 
bile acid concentrations have been implicated in the 
pathogenesis of constipation. 
   3  Bile acids induce colonic secretion and motility and ac-
celerate colon transit. 
   3  The ileal bile acid transporter (IBAT) is responsible for the 
reuptake of bile acids from the terminal ileum. 
   3  The IBAT inhibitor A3309 acts locally to decrease bile acid 
reuptake and has been shown to accelerate colon transit in 
patients with chronic constipation. 
    WHAT IS NEW HERE   
   3  In a methodologically rigorous phase IIb trial, A3309 
provided rapid and sustained improvement in stool 
frequency and other constipation-related symptoms 
compared with placebo. 
   3  A3309 increased bile acid synthesis and reduced plasma 
low-density lipoprotein (LDL) cholesterol and the LDL  /  high-
density lipoprotein (HDL) ratio. 
   3  The most common adverse events with A3309 were 
abdominal pain and diarrhea. These adverse events 
appeared to be dose dependent. 
   3  In a dose  –  response evaluation, the 10-mg A3309 dose 
provided a good balance of efﬁ  cacy and safety and may be 
a suitable therapeutic alternative for patients with chronic 
constipation.                          The American Journal of GASTROENTEROLOGY  VOLUME 106 | OCTOBER 2011   www.amjgastro.com
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